Pioneering genetic-testing company Myriad's biggest new product is facing pushback from US regulators that could 'significantly limit' the test's appeal. The stock is down 40%.

This story requires our BI Prime membership. To read the full article, simply click here to claim your deal and get access to all exclusive…

Read More Pioneering genetic-testing company Myriad's biggest new product is facing pushback from US regulators that could 'significantly limit' the test's appeal. The stock is down 40%.